<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00217399</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00069</org_study_id>
    <secondary_id>NCI-2009-00069</secondary_id>
    <secondary_id>CDR0000440067</secondary_id>
    <secondary_id>2004-251</secondary_id>
    <secondary_id>2004-251</secondary_id>
    <secondary_id>6584</secondary_id>
    <nct_id>NCT00217399</nct_id>
  </id_info>
  <brief_title>Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I/II Trial of BAY 43-9006 (Sorafenib) in Combination With Anastrozole in Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor and by
      blocking some of the enzymes needed for cell growth. Estradiol can cause the growth of breast
      cancer. Hormone therapy using anastrozole may fight breast cancer by blocking the use of
      estradiol by the tumor cells. Sometimes when hormone therapy is given, it does not stop the
      growth of tumor cells. The tumor is said to be resistant to hormone therapy. Giving sorafenib
      together with anastrozole may reduce drug resistance and allow the tumor cells to be killed.
      This phase I/II trial is studying the side effects and best dose of sorafenib when given in
      combination with anastrozole and to see how well they work in treating postmenopausal women
      with metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the clinical benefit rate of sorafenib in combination with anastrazole in women
      with estrogen receptor- and/or progesterone receptor-positive metastatic breast cancer.

      II. Determine the recommended phase II dose of sorafenib when administered with anastrozole
      in these patients.

      SECONDARY OBJECTIVES:

      I. Determine the toxic effects of this regimen in these patients. II. Determine the changes
      in Raf-MAPK and VEGF-signaling pathways in tumor tissue and stroma before and after treatment
      with this regimen in these patients.

      OUTLINE: This is a multicenter, dose-escalation study of sorafenib.

      PHASE I: Patients receive oral sorafenib twice daily and oral anastrozole once daily on days
      1-28.

      Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
      Cohorts of 3-6 patients receive escalating doses of sorafenib until the maximum tolerated
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6
      patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the MTD.

      PHASE II: Patients receive sorafenib at the MTD and anastrozole as in phase I.

      After completion of study treatment, patients are followed every 4-8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response + Partial Response + Stable Disease &gt; 24 Weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Clinical Outcome measured using Response Evaluation Criteria In Solid Tumors (RECIST,)V1.0, and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), a tumor that is neither growing nor shrinking.
A patient has clinical benefit from treatment if CR + PR + SD &gt; 24 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients treated with the sorafenib / anastrozole combination who experienced Grade 1-4 adverse events according to NCI common terminology criteria for adverse events (CTCAE) version 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Marker Analysis</measure>
    <time_frame>1 year</time_frame>
    <description>Number of participants with significant change in the following circulating tumor biomarkers, measured by flow cytometry: cluster designation (CD)146, CD133. Values were normalized by CD45 values(ie CD146+/CD45- and CD133+/CD45-).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHASE I: Patients receive oral sorafenib twice daily and oral anastrozole once daily on days 1-28.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of sorafenib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the MTD.
PHASE II: Patients receive sorafenib at the MTD and anastrozole as in phase I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>BAY 43-9006</other_name>
    <other_name>BAY 43-9006 Tosylate Salt</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>SFN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>ANAS</other_name>
    <other_name>Arimidex</other_name>
    <other_name>ICI-D1033</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed breast cancer

          -  Metastatic disease

          -  Measurable disease, defined as &gt;=1 unidimensionally measurable lesion, including &gt;= 1
             of the following:

               -  Lesion &gt;= 10 mm on CT scan (5 mm sections)

               -  Lesion &gt;= 20 mm on CT scan or MRI (10 mm sections)

               -  Bone disease that is &gt;= 10 mm on MRI

               -  Lytic bone lesions that are &gt;= 10 mm on CT scan (with 5 mm sections) OR &gt;= 20 mm
                  on plain film or CT scan (with 10 mm sections)

               -  Lesion &gt;= 10 mm on physical exam

          -  Patients must have received &gt;= 1 prior aromatase inhibitor in either the adjuvant or
             metastatic setting and must have had either disease recurrence or disease progression
             on a prior aromatase inhibitor therapy

          -  No brain metastases diagnosed within the past 6 months OR previously untreated brain
             metastases

          -  Estrogen receptor-positive and/or progesterone receptor-positive, defined as &gt; 1%
             staining by immunohistochemistry or &gt; 10 fmol/mg of protein by radio-ligand
             dextran-coated steroid binding assay

          -  Postmenopausal, as defined by 1 of the following:

               -  Prior bilateral oophorectomy

               -  No menses for &gt;= 12 months in patients with an intact uterus

               -  Follicle-stimulating hormone (FSH) in postmenopausal range in patients &lt; 60 years
                  of age who have had a prior hysterectomy or have been amenorrheic for &gt;= 3 months

               -  Age &gt;= 60 years

               -  Pre- or perimenopausal patients receiving monthly injections of goserelin at a
                  dose of 3.6 mg are eligible

          -  ECOG 0-2

          -  More than 3 months

          -  Absolute neutrophil count &gt;= 1,500/mm3 Platelet count &gt;= 100,000/mm3 No bleeding
             diathesis

          -  Bilirubin =&lt; 1.5 times upper limit of normal (ULN AST and ALT =&lt; 2.5 times ULN

          -  Systolic blood pressure (BP) &lt; 150 mm Hg and diastolic BP &lt; 100 mm Hg on at least one
             reading prior to study entry No uncontrolled hypertension

          -  None of the following within the past 6 months:

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Myocardial infarction

               -  Cardiac arrhythmia with hemodynamic compromise

          -  Not pregnant or nursing

          -  Able to swallow oral medication

          -  No known HIV positivity

          -  No ongoing or active infection

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No other active invasive malignancy within the past 5 years except nonmelanoma skin
             cancer or treated carcinoma in situ of the cervix

          -  No other uncontrolled illness

          -  More than 4 weeks since prior chemotherapy

          -  No more than 2 prior chemotherapy regimens for metastatic disease

          -  At least 8 weeks since prior anastrozole therapy

          -  Concurrent steroids allowed if dose is stable

          -  More than 4 weeks since prior radiotherapy

          -  More than 4 weeks since prior major surgery

          -  Recovered from prior therapy

          -  No prior sorafenib

          -  No concurrent therapeutic anticoagulation

          -  Concurrent prophylactic anticoagulation (i.e., low-dose warfarin) for venous or
             arterial access devices allowed provided PT and PTT are =&lt; 1.5 times ULN

          -  No concurrent agents that may interact with sorafenib, including any of the following:

               -  Hypericum perforatum (St. John's wort)

               -  Rifampin

               -  P450 CYP3A4 enzyme-inducing anticonvulsants (e.g., phenytoin, carbamazepine, or
                  phenobarbital)

          -  No other concurrent investigational agents

        Exclusion Criteria:

          -  estrogen receptor status unknown

          -  history of myocardial infarction within 6 months

          -  performance status 3

          -  performance status 4

          -  premenopausal

          -  progesterone receptor status unknown

          -  HIV positive
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudine Isaacs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lombardi Comprehensive Cancer Center at Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lombardi Comprehensive Cancer Center at Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>March 23, 2011</results_first_submitted>
  <results_first_submitted_qc>January 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 12, 2013</results_first_posted>
  <last_update_submitted>May 12, 2014</last_update_submitted>
  <last_update_submitted_qc>May 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 22-Sep-2005 through 01-Jul-2009</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sorafenib and Anastrozole</title>
          <description>A single arm of 35 patients with advanced or metastatic breast cancer receiving a combination of sorafenib and anastrozole.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sorafenib and Anastrozole</title>
          <description>A single arm of 35 patients with advanced or metastatic breast cancer receiving a combination of sorafenib and anastrozole.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Response + Partial Response + Stable Disease &gt; 24 Weeks</title>
        <description>Clinical Outcome measured using Response Evaluation Criteria In Solid Tumors (RECIST,)V1.0, and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), a tumor that is neither growing nor shrinking.
A patient has clinical benefit from treatment if CR + PR + SD &gt; 24 weeks.</description>
        <time_frame>24 weeks</time_frame>
        <population>Female patients with advanced or metastatic breast cancer. The protocol was initiated with intention to treat every patient enrolled with a sorafenib and anastrozole combination.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib and Anastrozole</title>
            <description>All patients receive sorafenib and anastrozole.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response + Partial Response + Stable Disease &gt; 24 Weeks</title>
          <description>Clinical Outcome measured using Response Evaluation Criteria In Solid Tumors (RECIST,)V1.0, and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), a tumor that is neither growing nor shrinking.
A patient has clinical benefit from treatment if CR + PR + SD &gt; 24 weeks.</description>
          <population>Female patients with advanced or metastatic breast cancer. The protocol was initiated with intention to treat every patient enrolled with a sorafenib and anastrozole combination.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="20" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Number of patients treated with the sorafenib / anastrozole combination who experienced Grade 1-4 adverse events according to NCI common terminology criteria for adverse events (CTCAE) version 3.0</description>
        <time_frame>1 year</time_frame>
        <population>All 35 patients enrolled in the study were assessed for adverse events according to NCI common terminology criteria for adverse events (CTCAE) version 3.0.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorefenib and Anastrozole</title>
            <description>All patients receive sorafenib (400mg by mouth twice daily) and anastrazole (1 mg by mouth daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Number of patients treated with the sorafenib / anastrozole combination who experienced Grade 1-4 adverse events according to NCI common terminology criteria for adverse events (CTCAE) version 3.0</description>
          <population>All 35 patients enrolled in the study were assessed for adverse events according to NCI common terminology criteria for adverse events (CTCAE) version 3.0.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Marker Analysis</title>
        <description>Number of participants with significant change in the following circulating tumor biomarkers, measured by flow cytometry: cluster designation (CD)146, CD133. Values were normalized by CD45 values(ie CD146+/CD45- and CD133+/CD45-).</description>
        <time_frame>1 year</time_frame>
        <population>14 subjects had blood specimens available for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Circulating Endothelial Cells</title>
            <description>All patients received sorafenib and anastrozole. Blood was drawn prior to beginning treatment and at set time points to analyze for circulating endothelial cells by flow cytometry</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Marker Analysis</title>
          <description>Number of participants with significant change in the following circulating tumor biomarkers, measured by flow cytometry: cluster designation (CD)146, CD133. Values were normalized by CD45 values(ie CD146+/CD45- and CD133+/CD45-).</description>
          <population>14 subjects had blood specimens available for analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sorafenib and Anastrozole</title>
          <description>A single arm of 35 patients with advanced or metastatic breast cancer receiving a combination of sorafenib and anastrozole.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE version 3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hand-foot syndome</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>CTCAE version 3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Emesis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>mucositis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>rigors/chills</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>elevated liver function tests</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>anthralgias</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>joint function</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>acne</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Claudine Isaacs</name_or_title>
      <organization>Georgetown University</organization>
      <phone>202-444-3677</phone>
      <email>isaacsc@georgetown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

